Several medications can significantly reduce binge eating episodes, though only one has full FDA approval for binge eating disorder (BED). The most effective options target different brain systems: impulse control, cravings, mood, and appetite signaling. Most people see noticeable improvement within 6 to 12 weeks of starting treatment.
The American Psychiatric Association recommends therapy as a first-line treatment for BED, specifically cognitive-behavioral therapy or interpersonal therapy. But for people who prefer medication, haven’t responded to therapy alone, or want a combined approach, several pharmaceutical options have strong evidence behind them.
Lisdexamfetamine: The Only FDA-Approved Option
Lisdexamfetamine (sold as Vyvanse) is the only medication with full FDA approval specifically for binge eating disorder in adults. It’s a stimulant that boosts dopamine and norepinephrine activity in the brain, improving impulse control and reducing the compulsive drive to binge. In clinical trials, patients taking 50 to 70 mg daily reduced their binge days by roughly 4 per week compared to baseline, a substantially larger drop than what placebo achieved.
Treatment typically starts at 30 mg daily, increasing by 20 mg each week until reaching a target dose of 50 to 70 mg. The most common side effects are dry mouth (affecting about 80% of patients), insomnia (56%), anxiety (25%), and headache (25%). Heart palpitations and teeth grinding also occur in some people.
Because it’s a stimulant, lisdexamfetamine isn’t appropriate for everyone. People with structural heart problems, serious arrhythmias, coronary artery disease, or cardiomyopathy should avoid it. If you have a history of substance abuse, that’s an important conversation to have with your prescriber, since the medication carries some potential for dependence. It also can’t be combined with a class of antidepressants called MAOIs.
Antidepressants for Binge Eating and Mood
SSRIs are the most commonly used antidepressants for binge eating, and the APA lists them alongside lisdexamfetamine as a suggested option. They work by increasing serotonin availability in the brain, which helps regulate mood, anxiety, and the obsessive thought patterns that often fuel binges. Across eight randomized controlled trials lasting 6 to 20 weeks, SSRIs consistently decreased both binge eating frequency and weight.
Sertraline and fluoxetine are the two most studied SSRIs for BED. A head-to-head trial comparing them over six months found no significant difference between the two. Both produced meaningful improvement in binge eating scores by week 8, and responders maintained those gains through the full 24 weeks. Fluvoxamine has also shown significant reductions in binge frequency and BMI in controlled trials. The advantage of SSRIs over stimulants is their lower side effect burden and the fact that they directly address the depression and anxiety that frequently accompany BED. The tradeoff is that they tend to produce more modest reductions in binge frequency.
Topiramate: Strong Results, More Side Effects
Topiramate is an anticonvulsant medication used off-label for BED that works through a different pathway, affecting a brain signaling chemical called glutamate that plays a role in food intake and compulsive behavior. The evidence for it is impressive. In a 14-week trial, patients taking topiramate reduced their binge frequency by 94%, compared to 46% in the placebo group. They also lost an average of 5.9 kg (about 13 pounds) versus 1.2 kg for placebo.
A larger 16-week trial with nearly 400 participants confirmed these results: binge days dropped from 4.6 per week down to 0.9 with topiramate, compared to 4.6 down to 2.2 with placebo. When added to cognitive-behavioral therapy, topiramate boosted binge eating remission rates to 84% versus 61% for therapy plus placebo, and patients lost about 7% of their body weight.
The catch is tolerability. Topiramate’s most distinctive side effects include tingling or numbness in the hands and feet (paresthesia), drowsiness, fatigue, confusion, and coordination problems. Some people experience cognitive dulling, often described as difficulty finding words or feeling mentally foggy. These side effects cause a meaningful number of people to stop taking it, which is a key reason it hasn’t pursued or received FDA approval for BED despite strong efficacy data.
Naltrexone-Bupropion: Targeting Cravings
The combination of naltrexone and bupropion (sold together as Contrave) was developed based on the understanding that binge eating involves dysfunction in two brain systems at once: the reward circuits that drive food cravings and the appetite-regulating pathways in a brain region called the hypothalamus. Bupropion increases dopamine and norepinephrine activity, reducing food-related cravings. Naltrexone blocks opioid receptors, which decreases the pleasurable “hit” from palatable, high-calorie foods and reduces food-seeking behavior.
This combination is FDA-approved for weight management but not specifically for BED. However, the neurobiological overlap between binge eating and other compulsive behaviors, particularly the shared disruption in dopamine and opioid signaling, provides a rationale for its use. Research has confirmed that both reduced self-control (from underactive prefrontal brain areas) and dysfunctional reward pathways are hallmarks of BED, and this drug combination addresses both.
GLP-1 Medications: A Newer Option
GLP-1 receptor agonists, the class of medications that includes liraglutide, semaglutide, and dulaglutide, are generating significant interest for binge eating. These drugs mimic a gut hormone that regulates appetite and fullness, and many patients report a dramatic reduction in what’s been called “food noise,” the constant mental preoccupation with eating.
In a controlled trial of 44 people with obesity who binge eat, those taking liraglutide saw their binge eating severity scores drop from 20 to 11 over 12 weeks, a much larger improvement than diet and exercise guidance alone. Research on semaglutide has shown improved overeating control, reduced food cravings, and a lower preference for high-fat, high-calorie foods. One analysis found that semaglutide produced a larger decrease in binge eating scores than either lisdexamfetamine or topiramate. Dulaglutide has also outperformed a comparison medication for reducing binge eating frequency, body weight, and BMI.
These are still early findings from small studies and pilot trials. None of the GLP-1 medications currently have FDA approval for binge eating disorder. But the results so far are promising, and their side effect profile, primarily nausea and gastrointestinal discomfort, compares favorably to stimulants and anticonvulsants for many patients.
How Quickly Medications Work
Most people can expect to see a meaningful reduction in binge episodes within the first 6 to 12 weeks. SSRI trials have shown significant improvements in binge frequency as early as 6 weeks. Fluoxetine, sertraline, and citalopram all demonstrated faster rates of binge reduction compared to placebo within that timeframe. Topiramate trials typically showed significant effects at 14 to 16 weeks, though some improvement begins earlier.
One important caveat: most clinical trials have only tested medications for 6 to 24 weeks, so the long-term picture is less clear. Limited follow-up data exist beyond those windows. This is worth discussing with your prescriber, because BED tends to be a chronic condition, and a plan for what happens after the initial treatment period matters.
How These Medications Compare
Choosing a medication depends on your specific situation, including which symptoms bother you most, what other health conditions you have, and how you respond to side effects.
- Lisdexamfetamine has the strongest regulatory backing and works well for people whose binges feel driven by impulsivity. It’s not suitable if you have heart conditions or a history of stimulant misuse.
- Topiramate produces the largest reductions in both binge frequency and weight, but cognitive side effects limit who can tolerate it long-term.
- SSRIs are the gentlest option and make the most sense when depression or anxiety is a major part of the picture. Their effect on binge frequency is more modest.
- Naltrexone-bupropion targets the craving and reward cycle directly, which may suit people who describe binge eating as feeling like an addiction.
- GLP-1 medications appear to reduce the mental preoccupation with food itself, and early data suggest strong efficacy, but they lack formal approval for BED.
Medication works best as part of a broader approach. The APA’s guidelines position therapy as the foundation, with medication added when therapy alone isn’t enough or when a patient prefers a pharmaceutical option. Combining topiramate with cognitive-behavioral therapy, for example, produced higher remission rates than either treatment alone. Whatever medication path you explore, it addresses the biological drivers of binge eating while therapy builds the behavioral skills to sustain recovery.